Over 50,000 people are diagnosed with a myeloid neoplasm every year in the U.S. alone. A high-risk subset of these patients is unresponsive to current treatments and their survival is less than a year, a rate that has remained unchanged for the last 40 years. The long-term goal of our work is to improve the outcome for these patients. To accomplish this, research in the lab focuses on understanding the underlying genomic abnormalities in high-risk myeloid neoplasms, to identify new treatment options.
We use a variety of next-generation approaches to decipher the cancer genome.
Congratulations to Jeremy, 2020 recipient of the BSD Career Advancement for Postdocs Travel Award to present his work at the Thirteenth International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia
Molly Imgruet is recognized by the American Society of Hematology with an Abstract Achievement Award and oral presentation